Search Results

You are looking at 151 - 160 of 1,455 items for :

  • Refine by Access: All x
Clear All
Full access

Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis

Daphna Y. Spiegel, Matthew J. Boyer, Julian C. Hong, Christina D. Williams, Michael J. Kelley, Joseph K. Salama, and Manisha Palta

for a total of 6 months of perioperative systemic therapy for LARC. 12 The purpose of this study was to examine the population-based outcomes of patients with LARC treated with neoadjuvant CRT followed by surgery with or without AC using data from the

Full access

Perioperative Management of Anticoagulation and Antithrombotic Therapy

Presented by: Michael B. Streiff

according to thrombotic risks, the surgery, and the pharmacokinetics of the anticoagulant.” The BRIDGE Trial One major revision in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Associated Venous Thromboembolic Disease

Full access

Implementation of Systemic Hedgehog Inhibitors in Daily Practice as Neoadjuvant Therapy

Nikki Tang and Desiree Ratner

Although it can occur anywhere on the body, BCC is most likely to arise on the head and neck, which has the greatest ultraviolet exposure. Treatment of appropriately selected BCCs with standard excision or Mohs surgery results in high cure rates. Non

Full access

Bone Cancer

J. Sybil Biermann, Douglas R. Adkins, Mark Agulnik, Robert S. Benjamin, Brian Brigman, James E. Butrynski, David Cheong, Warren Chow, William T. Curry, Deborah A. Frassica, Frank J. Frassica, Kenneth R. Hande, Francis J. Hornicek, Robin L. Jones, Joel Mayerson, Sean V. McGarry, Brian McGrath, Carol D. Morris, Richard J. O'Donnell, R. Lor Randall, Victor M. Santana, Robert L. Satcher, Herrick J. Siegel, Margaret von Mehren, Mary Anne Bergman, and Hema Sundar

recommended for surveillance and treatment of late effects of surgery, RT, and chemotherapy in long-term survivors. Patients should be given a survivorship prescription to schedule follow-up with a multidisciplinary team. Fertility issues should be discussed

Full access

Successful Resection After Neoadjuvant Therapy in Pancreatic Adenocarcinoma

Parvin F. Peddi and Andrea Wang-Gillam

occlusion of splenic vein, portal vein, and SMV, with mild stranding near the SMA ( Figure 2 ). The decision was made to offer extended Whipple surgery with SMV and portal vein reconstruction in an attempt for a cure. The CA 19-9 level at this time was less

Full access

Management of Patients With Aggressive Nonmelanoma Skin Cancers

Presented by: Valencia D. Thomas, Michael K. Wong, and Andrew J. Bishop

A wide range of approaches exist for treating aggressive nonmelanoma skin cancers, including surgery, radiation therapy (RT), cytotoxic chemotherapy, systemic immunotherapy, and active surveillance. Selecting an appropriate therapeutic approach

Full access

Head and Neck Cancers, Version 2.2014

David G. Pfister, Sharon Spencer, David M. Brizel, Barbara Burtness, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, A. Dimitrios Colevas, Frank Dunphy, David W. Eisele, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Bruce H. Haughey, Wesley L. Hicks Jr, Ying J. Hitchcock, Antonio Jimeno, Merrill S. Kies, William M. Lydiatt, Ellie Maghami, Renato Martins, Thomas McCaffrey, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, Cristina P. Rodriguez, Sandeep Samant, David E. Schuller, Jatin P. Shah, Randal S. Weber, Gregory T. Wolf, Frank Worden, Sue S. Yom, Nicole R. McMillian, and Miranda Hughes

, and mucosal melanoma. 1 , 2 The complete version of the NCCN Guidelines for H&N Cancers is available at . Updates to these guidelines for 2014 include revisions to “Principles of Radiation Therapy” for each site and “Principles of Surgery

Full access

Metastatic Mucinous Ovarian Cancer and Treatment Decisions Based on Histology and Molecular Markers Rather Than the Primary Location

Angela Jain, Paula D. Ryan, and Michael V. Seiden

for craniectomies, and each lesion was excised over 2 different surgeries. This was followed by whole brain radiation. Figure 1 Liver metastases (A) pretreatment, (B) post FOLFOX (5-FU, leucovorin, and oxaliplatin) and bevacizumab, and (C) post

Full access

NCCN Task Force Report: Breast Cancer in the Older Woman

Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer

older woman. A total of 18 task force members represented medical oncology, radiation oncology, surgical oncology, geriatric oncology, geriatrics, plastic surgery, and patient advocacy. All task force members were identified and invited solely by NCCN. A

Full access

Breast Cancer Version 2.2015

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar

more effective treatment. 5 Treatment Approach The treatment of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and systemic treatment with chemotherapy, endocrine therapy, biologic therapy, or